Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz(St. Jude Children's Research Hospital), Hiroto Inaba(University of Tennessee Health Science Center), Gary V. Dahl(Lucile Packard Children's Hospital), Raul C. Ribeiro(University of Tennessee Health Science Center), W. Paul Bowman(Cook Children's Medical Center), Jeffrey W. Taub(Children's Hospital of Michigan), Stanley Pounds(University of Tennessee Health Science Center), Bassem I. Razzouk(University of Tennessee Health Science Center), Norman J. Lacayo(Lucile Packard Children's Hospital), Xueyuan Cao(University of Tennessee Health Science Center), Soheil Meshinchi(Fred Hutch Cancer Center), Barbara Degar(Dana-Farber Cancer Institute), Gladstone Airewele(Children's Cancer Center), Susana C. Raimondi(St. Jude Children's Research Hospital), Mihaela Onciu(University of Tennessee Health Science Center), Elaine Coustan‐Smith(St. Jude Children's Research Hospital), James R. Downing(St. Jude Children's Research Hospital), Wing Leung(University of Tennessee Health Science Center), Ching‐Hon Pui(University of Tennessee Health Science Center), Dario Campana(St. Jude Children's Research Hospital)
Cited by 581